This case involves a lawsuit against the CMS, with the plaintiff arguing that the agency's decision to introduce cannabinoid products into the Medicare population was premature. The case is ongoing, with the outcome uncertain. The plaintiff's argument challenges the CMS's authority to make such a decision, which has significant implications for the healthcare industry.
Latest development
Media Coverage · April 21, 2026
Former President Trump is advocating for the rescheduling of cannabis, as a federal lawsuit challenges the Centers for Medicare & Medicaid Services' decision to introduce hemp-derived cannabinoid access pathways into Medicare connected care models. The lawsuit, supported by clinicians and constitutional scholars, argues that federal healthcare reimbursement must follow scientific validation, not precede it. This
newspaper Read articleACCESS Newswire 22 Apr 2026, 00:09 GMT+10 'This isn't about being anti-cannabis. MMJ International Holdings followed the FDA botanical drug pathway from the beginning, and we are working through the same CMC requirements every pharmaceutical developer must meet. Federal healthcare programs should not introduce cannabinoid products into the Medicare population until those same standards are satisfied.' Why the SAM Lawsuit Against CMS Is Likely to Prevail - and Why It Matters for MMJ International
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
Former President Trump is advocating for the rescheduling of cannabis, as a federal lawsuit challenges the Centers for Medicare & Medicaid Services' decision to introduce hemp-derived cannabinoid access pathways into Medicare connected care models. The lawsuit, supported by clinicians and constitutional scholars, argues that federal healthcare reimbursement must follow scientific validation, not precede it. This case has significant implications for the cannabis industry, particularly for companies like MMJ International Holdings.
ACCESS Newswire 22 Apr 2026, 00:09 GMT+10 'This isn't about being anti-cannabis. MMJ International Holdings followed the FDA botanical drug pathway from the beginning, and we are working through the …
ACCESS Newswire 22 Apr 2026, 00:09 GMT+10 'This isn't about being anti-cannabis. MMJ International Holdings followed the FDA botanical drug pathway from the beginning, and we are working through the …
Sources tracked
2 outlets · 2 articles
Timeline events
1 record on file
Last updated
1 day, 6 hours ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.